Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
RVL Pharmaceuticals plc (OSMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/13/2023 8-K Quarterly results
09/29/2023 8-K Other Events  Interactive Data
08/25/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/25/2023 8-K Regulation FD Disclosure  Interactive Data
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/23/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/18/2023 8-K Quarterly results
08/17/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review"
08/02/2023 8-K Resignation/termination of a director
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update"
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/20/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/07/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/30/2023 SC 13D/A Avista Healthcare Partners GP, Ltd. reports a 23.9% stake in RVL Pharmaceuticals plc
01/27/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/09/2023 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/18/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ Net Product Sales"
08/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/19/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy